A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2011
03/24/2011	US20110070249 IMMUNIZING COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST THE Beta-SECRETASE CLEAVAGE SITE OF AMYLOID PRECURSOR PROTEIN
03/24/2011	US20110070237 Methods of modulating and identifying agents that modulate intracellular calcium
03/24/2011	US20110070234 Np1 activity regulating elements useful for the production of drugs for the treatment or prevention of human neurodegenerative diseases, resulting drugs and use thereof
03/24/2011	US20110070225 Beta antibody parenteral formulation
03/24/2011	US20110070209 Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs
03/24/2011	US20110070205 Multipotent stem cells and uses thereof
03/24/2011	US20110070202 Targeted delivery to the brain of magnetically labeled stem cells
03/24/2011	US20110070170 Manufacture of chewing gum product with radiofrequency
03/24/2011	US20110070169 Effervescent Oral Fentanyl Dosage Form and Methods of Administering Fentanyl
03/24/2011	CA2774515A1 Substituted phenylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
03/24/2011	CA2774375A1 Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
03/24/2011	CA2774374A1 Substituted benzamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
03/24/2011	CA2774373A1 Substituted heteroarylamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
03/24/2011	CA2774372A1 Substituted heteroarylamine carboxamide analogs as mglur5 negative allosteric modulators and methods of making and using the same
03/24/2011	CA2774359A1 Compositions and methods for treating seizure disorders
03/24/2011	CA2774355A1 Compositions and methods for treating spasticity
03/24/2011	CA2774350A1 Novel peptides isolated from spider venom, and uses thereof
03/24/2011	CA2773592A1 Method and composition for treating alzheimer-type dementia
03/24/2011	CA2773555A1 Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
03/24/2011	CA2773552A1 Treatment of neurological conditions
03/24/2011	CA2772689A1 Glycine compound
03/24/2011	CA2771612A1 Selective calcium channel modulators
03/24/2011	CA2770932A1 Substituted n-phenyl-1-(4-pyridinyl)-1h-pyrazol-3-amines
03/23/2011	EP2298813A2 Anti-TRKB monoclonal antibodies and uses thereof
03/23/2011	EP2298807A2 Antibodies directed against amyloid-beta peptide and methods using same
03/23/2011	EP2298803A2 Human G-protein coupled receptor and ligands thereof
03/23/2011	EP2298776A1 Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
03/23/2011	EP2298775A1 Diazabicyclic central nervous system active agents
03/23/2011	EP2298773A1 6-Cyclomethyl and 6-alkylmethyl substituted pyrazolopyrimidines
03/23/2011	EP2298770A1 Heterocyclic compounds as TrkA modulators
03/23/2011	EP2298766A1 Substituted pyridine derivatives
03/23/2011	EP2298765A1 4-Oxadiazolyl-piperidine compounds and use thereof
03/23/2011	EP2298764A1 4-Oxadiazolyl-piperidine compounds and use thereof
03/23/2011	EP2298759A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases
03/23/2011	EP2298758A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases
03/23/2011	EP2298757A2 Urea compounds active as vanilloid receptor antagonist for the treatment of pain
03/23/2011	EP2298747A1 Triazole derivative or salt thereof
03/23/2011	EP2298744A2 Opioid receptor modulators
03/23/2011	EP2298738A1 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands
03/23/2011	EP2298734A2 Cyclobutyl amine derivatives
03/23/2011	EP2298731A1 Amide compound
03/23/2011	EP2298416A2 Sustained-release tramadol formulations with 24-hour clinical efficacy
03/23/2011	EP2298355A2 Albumin fusion proteins
03/23/2011	EP2298329A1 Methods of reducing beta-amyloid polypeptides
03/23/2011	EP2298328A1 Use of umbilical cord blood cells for the treatment of neurological disorders
03/23/2011	EP2298306A1 A method of analgesia
03/23/2011	EP2298303A1 Pharmaceutical combinations of hydrocodone and naltrexone
03/23/2011	EP2298301A2 Medicaments for increasing endogenous Erythropoietin (EPO)
03/23/2011	EP2298296A1 Composition and method for treating cognitive impairments in down syndrome subjects
03/23/2011	EP2298292A2 Kinase inhibitors for treating cancers
03/23/2011	EP2298291A2 Kinase inhibitors for treating cancers
03/23/2011	EP2298284A2 Mucoadhesive pharmaceutical formulations
03/23/2011	EP2298283A2 Pharmaceutical formulations comprising cannabinoids
03/23/2011	EP2298281A1 Infusion and injection solution of Levodopa
03/23/2011	EP2297341A1 Methods and compositions for the treatment of huntington's disease
03/23/2011	EP2297183A1 Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
03/23/2011	EP2297167A1 Selenophene and selenazole carboxylic acid derivatives
03/23/2011	EP2297166A1 Substituted n-imidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-ht6 ligands
03/23/2011	EP2297154A1 1- (7-(hexahydropyrrolo [3, 4-c]pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
03/23/2011	EP2297153A1 Limk2 inhibitors, compositions comprising them, and methods of their use
03/23/2011	EP2297152A1 Anhydrous crystal form of orvepitant maleate
03/23/2011	EP2297148A1 Novel derivatives of (bridged piperazinyl)-1-alcanone and use thereof as p75 inhibitors
03/23/2011	EP2297145A2 Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n- (1-methylpiperidin-4-yl)-9h-pyrido[2, 3-b]indole-7-carboxamide and methods of use therefor
03/23/2011	EP2297139A1 Compounds
03/23/2011	EP2297137A1 Novel heteroaryl carboxamide derivatives
03/23/2011	EP2297133A1 1, 2 disubstituted heterocyclic compounds
03/23/2011	EP2297131A2 Di-substituted phenyl compounds as phosphodiesterase 10 inhibitors
03/23/2011	EP2297128A1 Inhibitors of ikk- serine-threonine protein kinase
03/23/2011	EP2297127A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases
03/23/2011	EP2297120A1 Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
03/23/2011	EP2297110A1 Indane derivatives as ampa receptor modulators
03/23/2011	EP2297106A1 Phenoxypyridinylamide derivatives and their use in the treatment of pde4 mediated disease states
03/23/2011	EP2297098A1 Pyrrolidine derivatives as nk2 receptor antagonists
03/23/2011	EP2297087A2 Solid states of o-desmethylvenlaf axine salts
03/23/2011	EP2296684A1 Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
03/23/2011	EP2296681A2 A homeopathic formulation
03/23/2011	EP2296658A2 Nmda receptor antagonists for the treatment of neuropsychiatric disorders
03/23/2011	EP2296657A1 Method of treating anxious major depressive disorder
03/23/2011	EP2296656A1 Dihydrotetrabenanzine for the treatment of anxiety
03/23/2011	EP2296652A1 Topical regional neuro-affective therapy
03/23/2011	EP2296646A2 Novel treatments
03/23/2011	EP2296638A2 Identification of a molecular signature for antipsychotics and serms
03/23/2011	EP2296636A1 Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier
03/23/2011	EP2296634A1 Process for manufacture of a medicament with granulation and pan coating
03/23/2011	EP2296625A1 Pharmaceutical formulation of ketorolac for intranasal administration
03/23/2011	EP2296475A1 Triazolopyridine jak inhibitor compounds and methods
03/23/2011	EP2296472A1 Compounds for rho kinase inhibition and for improving learning and memory
03/23/2011	EP2296471A1 Muscarinic agonists as cognitive enhancers
03/23/2011	EP2296469A1 Kappa opioid receptor ligands
03/23/2011	EP2296462A1 Rasagiline for parkinson's disease modification
03/23/2011	EP2086643B1 Compounds which potentiate ampa receptor and uses thereof in medicine
03/23/2011	EP1942891B1 Novel combination of drugs as antidepressant
03/23/2011	EP1448205B1 Combinations for the treatment of immunoinflammatory disorders
03/23/2011	EP1351707B1 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
03/23/2011	EP1278748B1 Inhibitors of human phosphatidyl-inositol 3-kinase delta
03/23/2011	EP1140836B1 Amide compounds
03/23/2011	CN201767605U Feather pillow core
03/23/2011	CN201767299U Pillow for beauty
03/23/2011	CN1956965B Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high CB1/CB2 receptor subtype selectivity
03/23/2011	CN1951372B Solid oral dosage forms comprising valsartan and HCTZ

1 ... 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 ... 1833